Library Subscription: Guest
Critical Reviews™ in Oncogenesis

Published 4 issues per year

ISSN Print: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

FLT3 Signaling and the Development of Inhibitors That Target FLT3 Kinase Activity

Volume 17, Issue 2, 2012, pp. 199-209
DOI: 10.1615/CritRevOncog.v17.i2.50
Get accessGet access

ABSTRACT

The FMS-like receptor tyrosine kinase-3 (FLT3) plays a key role in hematopoietic development and is frequently mutated in patients with acute myeloid leukemia (AML). These mutations render FLT3 constitutively active, and patients harboring these mutations have a poor prognosis. Targeting the kinase activity of FLT3 with inhibitory compounds is therefore an attractive therapeutic option. Over the last few years, numerous FLT3 inhibitors have undergone clinical trials. Although some have been disappointing, some newer agents have shown promise. This review provides an overview of FLT3 signaling, recent progress with next-generation inhibitors, and unexpected hurdles encountered when combining FLT3 inhibitors with chemotherapy.

CITED BY
  1. Rassi Fuad El, Arellano Martha, Update on Optimal Management of Acute Myeloid Leukemia, Clinical Medicine Insights: Oncology, 7, 2013. Crossref

  2. Arellano Martha, Carlisle Jennifer Wilkinson, How I treat older patients with acute myeloid leukemia, Cancer, 124, 12, 2018. Crossref

  3. Kyuno Daisuke, Zhao Kun, Schnölzer Martina, Provaznik Jan, Hackert Thilo, Zöller Margot, Claudin7‐dependent exosome‐promoted reprogramming of nonmetastasizing tumor cells, International Journal of Cancer, 145, 8, 2019. Crossref

  4. Hartwell Kimberly A, Miller Peter G, Mukherjee Siddhartha, Kahn Alissa R, Stewart Alison L, Logan David J, Negri Joseph M, Duvet Mildred, Järås Marcus, Puram Rishi, Dancik Vlado, Al-Shahrour Fatima, Kindler Thomas, Tothova Zuzana, Chattopadhyay Shrikanta, Hasaka Thomas, Narayan Rajiv, Dai Mingji, Huang Christina, Shterental Sebastian, Chu Lisa P, Haydu J Erika, Shieh Jae Hung, Steensma David P, Munoz Benito, Bittker Joshua A, Shamji Alykhan F, Clemons Paul A, Tolliday Nicola J, Carpenter Anne E, Gilliland D Gary, Stern Andrew M, Moore Malcolm A S, Scadden David T, Schreiber Stuart L, Ebert Benjamin L, Golub Todd R, Niche-based screening identifies small-molecule inhibitors of leukemia stem cells, Nature Chemical Biology, 9, 12, 2013. Crossref

  5. Beaudin Anna E., Boyer Scott W., Forsberg E. Camilla, Flk2/Flt3 promotes both myeloid and lymphoid development by expanding non–self-renewing multipotent hematopoietic progenitor cells, Experimental Hematology, 42, 3, 2014. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain